Skip to main content
TipRanks
Go Ultimate75% OFF

Zhaoke Ophthalmology Ltd. (6622) AI Stock Analysis

2 Followers
HK:6622

Zhaoke Ophthalmology Ltd.

(HKEX:6622)

Select Model
Rating:41Neutral
Price Target:HKD 2.00â–¼(-0.74% Downside)
Action:reiterated
Date:11/07/26

The score is primarily constrained by substantial operating losses and persistent cash burn, despite a strong equity base and low leverage. Weak technical momentum and a negative P/E ratio provide additional headwinds.

Positive Factors
Modest LeverageModest leverage gives Zhaoke greater financial flexibility than a highly debt-funded biotech and reduces near-term pressure from interest obligations. The sizable equity base provides some capacity to continue developing its ophthalmology portfolio, although this cushion depends on containing future losses.
Negative Factors
Persistent UnprofitabilityThe deterioration in revenue and negative gross profit show that the current commercial model is not yet covering product-level costs. Persistent operating and net losses weaken the evidence for scalable economics and could require management to rely on external funding while the portfolio develops.

Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-40%-30%-20%-10%0%10%20%HK:6622-36.64%EWH+9.24%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.08B
Dividend Yield
―
Average Volume (3M)
184.79K
Price to Earnings (P/E)
-4.5
Beta (1Y)
1.77
Revenue Growth
2.56%
EPS Growth
20.20%
Country
Hong Kong
Employees
285
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model

Company Description

Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is a...

Zhaoke Ophthalmology Ltd. Financial Statement Overview

Summary

Revenue reached $31M in 2025, but gross losses, a -653% net margin, $260M negative operating cash flow, and ongoing cash burn weigh heavily on performance. The $1.6B equity base and low debt-to-equity ratio provide important financial stability.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue34.75M31.15M69.32M18.75M00
Gross Profit-35.42M-32.57M51.80M14.25M00
EBITDA-216.50M-214.09M-231.34M-327.86M-377.26M-373.04M
Net Income-213.55M-203.57M-237.49M-385.04M-407.32M-2.13B
Balance Sheet
Total Assets1.74B1.94B2.24B2.42B2.57B2.61B
Cash, Cash Equivalents and Short-Term Investments1.01B1.30B1.19B1.46B1.73B2.14B
Total Debt266.51M292.48M238.59M238.03M131.93M37.03M
Total Liabilities349.79M359.58M343.44M372.02M222.25M109.92M
Stockholders Equity1.39B1.58B1.90B2.05B2.35B2.50B
Cash Flow
Free Cash Flow-176.78M-265.04M-297.79M-418.93M-569.60M-339.63M
Operating Cash Flow-172.56M-260.20M-253.72M-323.66M-331.05M-245.14M
Investing Cash Flow-326.01M109.11M-116.45M-75.77M-324.57M683.52M
Financing Cash Flow-10.70M45.63M-12.12M99.29M76.23M1.66B

Zhaoke Ophthalmology Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price2.02

Price Trends

50DMA2.27Negative
100DMA2.41Negative
200DMA2.72Negative

Market Momentum

MACD-0.03Negative
RSI46.52Neutral
STOCH82.33Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Negative. The current price of 2.02 is below the 20-day moving average (MA) of 2.05, below the 50-day MA of 2.27, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 82.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6622.

Zhaoke Ophthalmology Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:6622 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1477HK:147743NeutralHKD 3.94B-26.77-3.44%―77.55%50.34%
HK:6622HK:662241NeutralHKD 1.11B-4.50-14.41%―2.56%20.20%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%HK:6622HK:1477Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6622 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6622Zhaoke Ophthalmology Ltd.2.02-1.21-37.62%
HK:1477Ocumension Therapeutics4.83-3.28-40.46%

Zhaoke Ophthalmology Ltd. Corporate Events

Zhaoke Ophthalmology’s Cyclosporine Ophthalmic Gel Receives NMPA Marketing Approval

Nov 13, 2026

Zhaoke Ophthalmology’s self-developed Cyclosporine Ophthalmic Gel received marketing approval from the National Medical Products Administration on 10 November 2026 for promoting tear secretion and improving ocular signs in dry-eye patients with reduc...

Zhaoke Ophthalmology Wins Australian GMP Nod for Guangzhou Plant

Oct 27, 2026

Zhaoke Ophthalmology has secured Good Manufacturing Practice certification from Australia’s Therapeutic Goods Administration for its manufacturing facility in Nansha, Guangzhou, China. The TGA is a member of the Pharmaceutical Inspection Co-operation...

Zhaoke Ophthalmology’s Presbyopia Drug YUVEZZI™ Clears Phase II Milestone in China

Sep 4, 2026

Zhaoke Ophthalmology Limited announced that its innovative presbyopia therapy, carbachol and brimonidine tartrate ophthalmic solution (YUVEZZIâ„¢), met the prespecified primary endpoint in a Phase II clinical study in Chinese patients. The multicenter,...

Zhaoke Ophthalmology Posts Higher Revenue but Sustains Heavy R&D-Driven Losses in First Half 2026

Aug 28, 2026

Zhaoke Ophthalmology Limited reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB18.8 million, up from RMB15.8 million a year earlier, and gross profit rising to RMB9.7 million. Despite this top-line growt...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026